Jeffrey Edward Nelson Sells 58,007 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

30 Jan 2026, 10:56 by Mitch Edgeman · The Markets Daily

Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Get Free Report) COO Jeffrey Edward Nelson sold 58,007 shares of the stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24. Following the transaction, the chief operating officer owned 41,993 shares of the company’s stock, valued at approximately $97,423.76. This represents a 58.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jeffrey Edward Nelson also recently made the following trade(s):

On Monday, January 26th, Jeffrey Edward Nelson sold 12,245 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $23,632.85.

Milestone Pharmaceuticals Stock Performance

Shares of NASDAQ MIST opened at $1.89 on Friday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The stock has a 50 day moving average price of $2.23 and a 200 day moving average price of $1.96. The stock has a market capitalization of $160.97 million, a PE ratio of -2.30 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 52 week low of $0.63 and a 52 week high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. Analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors have recently made changes to their positions in MIST. Sapient Capital LLC acquired a new position in shares of Milestone Pharmaceuticals in the third quarter valued at approximately $25,000. Bank of America Corp DE boosted its stake in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after purchasing an additional 16,044 shares during the period. Stephenson & Company Inc. acquired a new position in Milestone Pharmaceuticals in the 3rd quarter valued at $40,000. Creative Planning increased its position in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after buying an additional 10,000 shares during the period. Finally, Bay Rivers Group increased its position in Milestone Pharmaceuticals by 72.9% during the 4th quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after buying an additional 12,170 shares during the period. Institutional investors own 86.18% of the company’s stock.

Key Stories Impacting Milestone Pharmaceuticals

Here are the key news stories impacting Milestone Pharmaceuticals this week:

Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short‑term buyers and momentum flows into a thinly traded microcap. Read More.
Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50‑day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double‑digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wells Fargo & Company lifted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

View Our Latest Stock Analysis on Milestone Pharmaceuticals

Milestone Pharmaceuticals Company Profile

(Get Free Report)

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.